Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $78.27 +3.46%
EPS Growth %: +27.1%
Financial Fact:
Net income (loss): 937K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +27.1%
Financial Fact:
Net income (loss): 937K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q4 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $180.7 million versus the consensus estimate of $179.2 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
